Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy.

Frasca K, Morrow M, Coyle RP, Coleman SS, Ellison L, Bushman LR, Kiser JJ, Zheng JH, Mawhinney S, Anderson PL, Castillo-Mancilla J.

J Antimicrob Chemother. 2019 Jan 18. doi: 10.1093/jac/dky559. [Epub ahead of print]

PMID:
30668713
2.

A meta-analytic examination of attrition in virtual reality exposure therapy for anxiety disorders.

Benbow AA, Anderson PL.

J Anxiety Disord. 2019 Jan;61:18-26. doi: 10.1016/j.janxdis.2018.06.006. Epub 2018 Jun 21.

PMID:
30646997
3.

Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking.

Hoenigl M, Morgan E, Franklin D, Anderson PL, Pasipanodya E, Dawson M, Hanashiro M, Ellorin EE, Blumenthal J, Heaton R, Moore DJ, Morris SR; California Collaborative Treatment Group (CCTG) 601 Team.

J Neurovirol. 2019 Jan 7. doi: 10.1007/s13365-018-0716-3. [Epub ahead of print]

PMID:
30617849
4.

The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing PrEP Regimens in Men who have Sex with Men.

McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R.

AIDS. 2018 Dec 13. doi: 10.1097/QAD.0000000000002038. [Epub ahead of print]

PMID:
30570571
5.

The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.

McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R.

AIDS. 2019 Feb 1;33(2):237-246. doi: 10.1097/QAD.0000000000002038.

PMID:
30557160
6.

Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.

Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, Okochi H, Anderson PL, Kearney MF, Coffey S, Scott H, Grant RM, Havlir D, Gandhi M.

Lancet HIV. 2018 Nov 29. pii: S2352-3018(18)30288-1. doi: 10.1016/S2352-3018(18)30288-1. [Epub ahead of print]

PMID:
30503324
7.

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1.

Hoenigl M, Jain S, Moore D, Collins D, Sun X, Anderson PL, Corado K, Blumenthal JS, Daar ES, Milam J, Dubé MP, Morris S; California Collaborative Treatment Group 595 Team.

Emerg Infect Dis. 2018 Dec;24(12). doi: 10.3201/eid2412.180400.

8.

Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048.

Liu AY, Zhang J, Anderson PL, Wagner T, Pan Z, Peda M, Gomez K, Beamer M, Jacobson C, Strizki J, Dezzutti CS, Piper JM; MTN-028 Protocol Team for the Microbicide Trials Network.

Clin Infect Dis. 2018 Oct 4. doi: 10.1093/cid/ciy652. [Epub ahead of print]

PMID:
30289444
9.

Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.

Hoesley CJ, Chen BA, Anderson PL, Dezzutti CS, Strizki J, Sprinkle C, Heard F, Bauermeister J, Hall W, Jacobson C, Berthiaume J, Mayo A, Gundacker H, Richardson-Harman N, Piper J; Microbicide Trials Network 027 Study Team.

Clin Infect Dis. 2018 Oct 4. doi: 10.1093/cid/ciy653. [Epub ahead of print]

PMID:
30289435
10.

Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.

Havens PL, Tamhane A, Stephensen CB, Schuster GU, Gordon CM, Liu N, Wilson CM, Hosek SG, Anderson PL, Kapogiannis BG, Mulligan K.

AIDS Res Hum Retroviruses. 2019 Feb;35(2):123-128. doi: 10.1089/AID.2018.0096. Epub 2018 Nov 5.

PMID:
30280906
11.

Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Pre-exposure Prophylaxis among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study.

Liu AY, Vittinghoff E, von Felten P, Amico KR, Anderson PL, Lester R, Andrew E, Estes I, Serrano P, Brothers J, Buchbinder S, Hosek S, Fuchs JD.

Clin Infect Dis. 2018 Sep 15. doi: 10.1093/cid/ciy810. [Epub ahead of print]

PMID:
30239620
12.

Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.

Koss CA, Liu AY, Castillo-Mancilla J, Bacchetti P, McHugh C, Kuncze K, Morrow M, Louie A, Seifert S, Okochi H, MaWhinney S, Gandhi M, Anderson PL.

AIDS. 2018 Sep 24;32(15):2189-2194. doi: 10.1097/QAD.0000000000001935.

PMID:
30212404
13.

Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.

Brooks KM, Anderson PL.

Clin Pharmacol Ther. 2018 Dec;104(6):1056-1059. doi: 10.1002/cpt.1201. Epub 2018 Sep 4. No abstract available.

PMID:
30178462
14.

Tenofovir Diphosphate in Dried Blood Spots is Strongly Associated with Viral Suppression in Individuals with HIV infection.

Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL.

Clin Infect Dis. 2018 Aug 23. doi: 10.1093/cid/ciy708. [Epub ahead of print]

PMID:
30137238
15.

Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing.

Innes S, van der Laan L, Anderson PL, Cotton M, Denti P.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00761-18. doi: 10.1128/AAC.00761-18. Print 2018 Nov.

16.

Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.

Chua CYX, Jain P, Ballerini A, Bruno G, Hood RL, Gupte M, Gao S, Di Trani N, Susnjar A, Shelton K, Bushman LR, Folci M, Filgueira CS, Marzinke MA, Anderson PL, Hu M, Nehete P, Arduino RC, Sastry JK, Grattoni A.

J Control Release. 2018 Sep 28;286:315-325. doi: 10.1016/j.jconrel.2018.08.010. Epub 2018 Aug 6.

PMID:
30092254
17.

In-capillary microextraction for direct mass spectrometry analysis of biological samples.

Ren Y, Zhang W, Lin Z, Bushman LR, Anderson PL, Ouyang Z.

Talanta. 2018 Nov 1;189:451-457. doi: 10.1016/j.talanta.2018.07.027. Epub 2018 Jul 11.

18.

Cryopreservation of human mucosal tissues.

Hughes SM, Ferre AL, Yandura SE, Shetler C, Baker CAR, Calienes F, Levy CN, Astronomo RD, Shu Z, Lentz GM, Fialkow M, Kirby AC, McElrath MJ, Sinclair E, Rohan LC, Anderson PL, Shacklett BL, Dezzutti CS, Gao D, Hladik F.

PLoS One. 2018 Jul 30;13(7):e0200653. doi: 10.1371/journal.pone.0200653. eCollection 2018.

19.

Deterioration rates in Virtual Reality Therapy: An individual patient data level meta-analysis.

Fernández-Álvarez J, Rozental A, Carlbring P, Colombo D, Riva G, Anderson PL, Baños RM, Benbow AA, Bouchard S, Bretón-López JM, Cárdenas G, Difede J, Emmelkamp P, García-Palacios A, Guillén V, Hoffman H, Kampann I, Moldovan R, Mühlberger A, North M, Pauli P, Peñate Castro W, Quero S, Tortella-Feliu M, Wyka K, Botella C.

J Anxiety Disord. 2019 Jan;61:3-17. doi: 10.1016/j.janxdis.2018.06.005. Epub 2018 Jul 17.

PMID:
30057346
20.

Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor.

Ibrahim ME, Brooks KM, Castillo-Mancilla JR, McHugh C, Morrow M, Brothers J, MaWhinney S, Hosek S, Huhn G, Anderson PL.

AIDS Res Hum Retroviruses. 2018 Oct;34(10):835-837. doi: 10.1089/AID.2018.0081. Epub 2018 Sep 5.

PMID:
30047286
21.

Similar tenofovir hair concentrations in men and women after directly-observed: dosing of TDF/FTC: implications for PrEP adherence monitoring.

Koss CA, Liu AY, Castillo-Mancilla J, Bacchetti P, Mchugh C, Kuncze K, Morrow M, Louie A, Seifert S, Okochi H, Mawhinney S, Gandhi M, Anderson PL.

AIDS. 2018 Jul 12. doi: 10.1097/QAD.0000000000001935. [Epub ahead of print]

PMID:
30005019
22.

Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.

Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, Thomas KK, Celum C, Donnell D, Marzinke MA, Bukusi EA, Mugo NR, Asiimwe S, Katabira E, Baeten JM; Partners Demonstration Study Team.

AIDS. 2018 Aug 24;32(13):1891-1898. doi: 10.1097/QAD.0000000000001922.

PMID:
29894385
23.

CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.

Monte AA, West K, McDaniel KT, Flaten HK, Saben J, Shelton S, Abdelmawla F, Bushman LR, Williamson K, Abbott D, Anderson PL.

Clin Pharmacol Ther. 2018 Nov;104(5):933-939. doi: 10.1002/cpt.1135. Epub 2018 Jul 25.

24.

Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study.

Child J, Chen X, Mistry RD, Somme S, MacBrayne C, Anderson PL, Jones RN, Parker SK.

J Pediatric Infect Dis Soc. 2018 May 16. doi: 10.1093/jpids/piy040. [Epub ahead of print]

PMID:
29788329
25.

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.

MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ.

J Antimicrob Chemother. 2018 Aug 1;73(8):2112-2119. doi: 10.1093/jac/dky146.

PMID:
29746648
26.

Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.

Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG; PrEP Brasil Study Team.

Lancet HIV. 2018 Mar;5(3):e136-e145. doi: 10.1016/S2352-3018(18)30008-0. Epub 2018 Feb 18.

PMID:
29467098
27.

Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.

Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, Stirratt M, Rooney JF, Eshleman SH, McNicholl JM, van Griensven F, Holtz TH.

Clin Infect Dis. 2018 May 17;66(11):1712-1721. doi: 10.1093/cid/cix1086.

PMID:
29420695
28.

Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

Clin Infect Dis. 2018 Jul 18;67(3):411-419. doi: 10.1093/cid/ciy083.

PMID:
29415175
29.

Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial.

Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, Anderson PL, Grant R, Greenblatt RM, Buchbinder S, Gandhi M, Liu AY.

PLoS One. 2018 Jan 9;13(1):e0190118. doi: 10.1371/journal.pone.0190118. eCollection 2018.

30.

Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.

Seifert SM, Castillo-Mancilla JR, Erlandson K, Morrow M, Gandhi M, Kuncze K, Horng H, Zheng JH, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL.

J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):295-298. doi: 10.1097/QAI.0000000000001596.

PMID:
29189417
31.

Continuum Reconfigurable Parallel Robots for Surgery: Shape Sensing and State Estimation with Uncertainty.

Anderson PL, Mahoney AW, Webster RJ 3rd.

IEEE Robot Autom Lett. 2017 Jul;2(3):1617-1624. doi: 10.1109/LRA.2017.2678606. Epub 2017 Mar 6.

32.

Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.

Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, Mohri H.

J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106. doi: 10.1097/QAI.0000000000001534. No abstract available.

33.

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.

Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01710-17. doi: 10.1128/AAC.01710-17. Print 2018 Jan.

34.

Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.

Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M.

Clin Infect Dis. 2018 Jan 6;66(2):213-219. doi: 10.1093/cid/cix755.

35.

Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.

Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY.

J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):193-198. doi: 10.1097/QAI.0000000000001566.

36.

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.

Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM; HPTN 067 (ADAPT) study team.

Lancet HIV. 2018 Feb;5(2):e68-e78. doi: 10.1016/S2352-3018(17)30156-X. Epub 2017 Oct 3.

37.

Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.

Hoornenborg E, Prins M, Achterbergh RCA, Woittiez LR, Cornelissen M, Jurriaans S, Kootstra NA, Anderson PL, Reiss P, de Vries HJC, Prins JM, de Bree GJ; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Consortium (H-TEAM).

Lancet HIV. 2017 Nov;4(11):e522-e528. doi: 10.1016/S2352-3018(17)30132-7. Epub 2017 Sep 14.

PMID:
28919303
38.

Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.

Landovitz RJ, Beymer M, Kofron R, Amico KR, Psaros C, Bushman L, Anderson PL, Flynn R, Lee DP, Bolan RK, Jordan WC, Tseng CH, Dierst-Davies R, Rooney J, Wohl AR.

J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):501-511. doi: 10.1097/QAI.0000000000001538.

39.

Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen.

Gandhi M, Murnane PM, Bacchetti P, Elion R, Kolber MA, Cohen SE, Horng H, Louie A, Kuncze K, Koss CA, Anderson PL, Buchbinder S, Liu A.

AIDS. 2017 Oct 23;31(16):2245-2251. doi: 10.1097/QAD.0000000000001615.

40.

Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users.

Lal L, Audsley J, Murphy DA, Fairley CK, Stoove M, Roth N, Moore R, Tee BK, Puratmaja N, Anderson PL, Leslie D, Grant RM, De Wit J, Wright E; VicPrEP Study Team.

AIDS. 2017 Jul 31;31(12):1709-1714. doi: 10.1097/QAD.0000000000001519.

PMID:
28700394
41.

Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):177-182. doi: 10.1097/QAI.0000000000001475.

42.

High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.

Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, Goulart S, Torres TS, Marins LMS, Anderson PL, Luz PM, Costa Leite ID, Liu AY, Veloso VG, Grinsztejn B; PrEP Brasil Study TeamClinical Trial Number 01989611.

J Int AIDS Soc. 2017 Apr 6;20(1):21472. doi: 10.7448/IAS.20.1.21472.

43.

Inflammation and pharmacokinetics: potential implications for HIV-infection.

Seifert SM, Castillo-Mancilla JR, Erlandson KM, Anderson PL.

Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):641-650. doi: 10.1080/17425255.2017.1311323. Epub 2017 Apr 3. Review.

PMID:
28335648
44.

Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.

Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH; HPTN 067/ADAPT Study Team.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):271-279. doi: 10.1097/QAI.0000000000001374.

45.

Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

Knox DC, Anderson PL, Harrigan PR, Tan DH.

N Engl J Med. 2017 Feb 2;376(5):501-502. doi: 10.1056/NEJMc1611639. No abstract available.

46.

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.

Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, Hance A, Goldwirt L, Morel S, Mammano F, Loze B, Capitant C, Clavel F, Mahjoub N, Meyer L, Anderson PL, Delaugerre C, Molina JM.

J Antimicrob Chemother. 2017 Feb;72(2):478-485. doi: 10.1093/jac/dkw412. Epub 2016 Sep 28.

PMID:
28073964
47.

Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.

Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team.

Clin Infect Dis. 2017 Feb 1;64(3):317-325. doi: 10.1093/cid/ciw765. Epub 2016 Nov 15.

48.

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.

Chen X, Seifert SM, Castillo-Mancilla JR, Bushman LR, Zheng JH, Kiser JJ, MaWhinney S, Anderson PL.

PLoS One. 2016 Nov 10;11(11):e0165505. doi: 10.1371/journal.pone.0165505. eCollection 2016.

49.

A Case Series on the Effects of Kripalu Yoga for Generalized Anxiety Disorder.

Morgan JR, Sullivan M, Masuda A, Tully E, Cohen LL, Anderson PL.

Int J Yoga Therap. 2016 Jan;26(1):9-19.

PMID:
27797661
50.

Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.

Castillo-Mancilla JR, Brown TT, Erlandson KM, Palella FJ Jr, Gardner EM, Macatangay BJ, Breen EC, Jacobson LP, Anderson PL, Wada NI.

Clin Infect Dis. 2016 Dec 15;63(12):1661-1667. Epub 2016 Sep 22.

Supplemental Content

Loading ...
Support Center